Phosphate and bone fracture risk in chronic kidney disease patients. Issue 3 (17th October 2019)

• Record Type: Journal Article
• Authors: Fusaro, Maria; Holden, Rachel; Lok, Charmaine; Iervasi, Giorgio; Plebani, Mario; Aghi, Andrea; Gallieni, Maurizio; Cozzolino, Mario
• Is Part Of: Nephrology dialysis transplantation. Volume 36:Issue 3(2021)
• Page Start: 405
• Page End: 412
• Publication Date: 2019-10-17
• Subjects: bone fractures -- CKD -- MBD -- phosphate levels; Nephrology -- Periodicals; Hemodialysis -- Periodicals; Kidneys -- Transplantation -- Periodicals; Hemodialysis; Kidneys -- Transplantation; Nephrology; Periodicals; 616.61
• DOI: 10.1093/ndt/gfz196
• Languages: English
• ISSNs: 0931-0509

Abstract

Abstract: In chronic kidney disease (CKD), phosphate homoeostasis plays a central role in the development of mineral and bone disorder (MBD) together with decreased serum calcium and elevated serum parathyroid hormone, fibroblast growth factor 23 and sclerostin levels. Today there are only a few data exploring the direct role of abnormal phosphate homoeostasis and hyperphosphataemia in the development of CKD-MBD. On the other hand, several studies have looked at the link between hyperphosphataemia and cardiovascular morbidity and mortality in CKD, but there is a lack of evidence to indicate that lowering phosphate levels improves cardiovascular outcomes in this population. Furthermore, the impact of liberalizing phosphate targets on CKD-MBD progression and bone fracture is currently not known. In this review we discuss the central role of phosphate in the pathogenesis of CKD-MBD and how it may be associated with fracture risk, both in hyper- and hypophosphataemia.